Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company focused on precision oncology, developing cancer therapies that exploit synthetic lethality — targeting genetic vulnerabilities unique to tumor cells. The company became publicly traded in October 2021 through a de-SPAC merger with BCTG Acquisition Corp, a blank-check vehicle sponsored by BCTG Sponsor LLC, an affiliate of BVF Partners L.P. The combined company retained the Tango name and continues to file with the SEC as an operating public entity, most recently submitting an 8-K on August 11, 2026. Investors and analysts seeking complete filing history, sponsor details, and deal analytics for TNGX can access the full dataset by signing up at SpacDesk.